Increased Biomarker Testing Could Boost Oncology Market In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's oncology market is one of the fastest-growing subsectors with cancer now the second-leading cause of death in China. Although the cost of oncology drugs is often prohibitive, increased biomarker testing could help increase access to innovative cancer treatments in China